Healthcare Sector — Q2 FY24 Earnings Overview
3 companies reported. 2 bullish, 1 neutral, 0 bearish.
Average revenue growth: 13.3%
Sector sentiment: bullish
Aggregate revenue: ₹23,528 Cr
Average margin: 21.7%
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹12,003 Cr | +11% | 26.1% | neutral medium |
| Cipla | ₹6,678 Cr | +15% | 26.0% | bullish high |
| Apollohosp | ₹4,847 Cr | +14% | 13.0% | bullish high |
Key sector risks this quarter
Sunpharma · high
Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.
Cipla · highIndore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.
Sunpharma · mediumTaro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.
Sunpharma · mediumManagement sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.
Apollohosp · mediumInpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.